To accelerate clinical data delivery and power clinical outcomes for patientsParexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and Palantir Technologies, a leading builder of Artificial Intelligence (AI) systems, announced a multi-year strategic partnership to leverage AI to help enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharmaceutical customers. Under the collaboration, Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the highest level of safety and regulatory rigour. Parexel is the first CRO working with Palantir in this capacity, building on the companies’ existing collaboration over the past year."We're thrilled to expand our collaboration with Palantir — a leader in artificial intelligence technology — as we build on our application of AI to further improve clinical trial execution and advance our offerings in Real World Evidence, advanced analytics and Health Outcomes,” said Jonathan Shough, Chief Information Officer, Parexel. “Leveraging our internal Parexel expertise and our strategic partnership with Palantir, we have novel solutions already in use or various stages of development that demonstrate our commitment to being a fully digital CRO.”“Parexel is well positioned to rapidly scale our use of AI to enhance data quality and streamline the clinical trial process to better deliver for our customers and patients,” said Stephen Pyke, DIC, Chief Clinical Data and Digital Officer for Parexel and Chair of the Association of Clinical Research Organization’s (ACRO) AI/ML Committee. “Combining our end-to-end delivery model with Palantir’s world-class security, governance and Artificial Intelligence Platform will generate strategic insights to inform drug development and accelerate time to market.”“Parexel has embraced the principles of digital transformation using generative AI at remarkable speed and scale,” said Dr Lalarukh Haris Shaikh, Executive, Life Sciences at Palantir. “The company will significantly accelerate its business by untapping the value of data via an ontology constructed within Palantir Foundry and connecting it to the immense power of generative AI in AIP. We are delighted to deepen our exceptional collaboration with Parexel, empowering them to fully leverage the capabilities of AIP and Foundry throughout their clinical processes and business operations.”
